View on Pubmed.gov 33963218 | View on doi.org 10.1038/s41598-...
Ubiquitin-mediated DNA damage response is synthetic lethal with G-quadruplex stabilizer CX-5461.
- Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, BC, V5Z 1L3, Canada.
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, V6T 2B5, Canada.
- Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, BC, V5Z 1L3, Canada. Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, V6T 2B5, Canada.
- Department of Molecular Oncology, BC Cancer Agency, 675 West 10th Avenue, Vancouver, BC, V5Z 1L3, Canada. saparicio@bccrc.ca.
- Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, V6T 2B5, Canada. saparicio@bccrc.ca.
Abstract
CX-5461 is a G-quadruplex (G4) ligand currently in trials with initial indications of clinical activity in cancers with defects in homologous recombination repair. To identify more genetic defects that could sensitize tumors to CX-5461, we tested synthetic lethality for 480 DNA repair and genome maintenance genes to CX-5461, pyridostatin (PDS), a structurally unrelated G4-specific stabilizer, and BMH-21, which binds GC-rich DNA but not G4 structures. We identified multiple members of HRD, Fanconi Anemia pathways, and POLQ, a polymerase with a helicase domain important for G4 structure resolution. Significant synthetic lethality was observed with UBE2N and RNF168, key members of the DNA damage response associated ubiquitin signaling pathway. Loss-of-function of RNF168 and UBE2N resulted in significantly lower cell survival in the presence of CX-5461 and PDS but not BMH-21. RNF168 recruitment and histone ubiquitination increased with CX-5461 treatment, and nuclear ubiquitination response frequently co-localized with G4 structures. Pharmacological inhibition of UBE2N acted synergistically with CX-5461. In conclusion, we have uncovered novel genetic vulnerabilities to CX-5461 with potential significance for patient selection in future clinical trials.
References
EMBO J. 2011 Aug 26;30(19):4033-46
Nucleic Acids Res. 2006 Feb 02;34(3):880-92
Mol Biotechnol. 2013 Mar;53(3):308-14
Oncotarget. 2016 Sep 27;7(39):64471-64504
Cited by 22 citations (total)
Journal Article Review
G-Quadruplexes and Their Ligands: Biophysical Methods to Unravel G-Quadruplex/Ligand Interactions.
Electronic publication date August 29, 2021
Tiago Santos [...] Carla Cruz et al.
Progress in the design of G-quadruplex (G4) binding ligands relies on the availability of approaches that assess the binding mode...
Journal Article Review
Targeting Ribosome Biogenesis in Cancer: Lessons Learned and Way Forward.
Electronic publication date May 15, 2022
Asimina Zisi [...] Mikael S Lindström et al.
Rapid growth and unrestrained proliferation is a hallmark of many cancers. To accomplish this, cancer cells re-wire and increase their...
Conflict of interest statement
MeSH
- •
- •
- •
- •
- •
- •
Specialties
- •
- •
- •
Substances
- •
- •
- •
- •
- •
- •
- •
- •